Chemomab Therapeutics (STU:2QV0) Treasury Stock : €0.00 Mil (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Chemomab Therapeutics Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Chemomab Therapeutics's treasury stock for the quarter that ended in Sep. 2024 was €0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Chemomab Therapeutics Treasury Stock Historical Data

The historical data trend for Chemomab Therapeutics's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chemomab Therapeutics Treasury Stock Chart

Chemomab Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Treasury Stock

-1.15

Chemomab Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Treasury Stock	Get a 7-Day Free Trial														-	-	-	-	-

Chemomab Therapeutics Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Chemomab Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chemomab Therapeutics Ltd (STU:2QV0) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

CMMB:USA

Address

Kiryat Atidim, Building 7, Tel Aviv, ISR, 6158002

Website

https://www.chemomab.com

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.

Chemomab Therapeutics Headlines

No Headlines